Marc Thill

Abstract PS2-09-09: Early on-treatment PD-L1 expression and stromal tumor infiltrating lymphocytes (sTILs) refine the prediction of EFS in the NeoTRIP trial

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025

AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025

Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025

Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk

Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer

Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer

A Multi-institutional Study to Evaluate the Effectiveness and Safety of a Supine MRI-Based Guidance System, the Breast Cancer Locator<sup>TM</sup>, for Breast Conserving Surgery in Patients with Nonpalpable Breast Cancer.

App-based support for breast cancer patients to reduce psychological distress during therapy and survivorship – a multicentric randomized controlled trial

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024

Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs

LBA1 Denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy in patients with primary breast cancer: Time to event analysis from the GeparX 2 × 2 randomized clinical trial

Spatial predictors of immunotherapy response in triple-negative breast cancer.

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial

Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.

AGO-Empfehlungen zur operativen Therapie des Mammakarzinoms: Update 2022

Effekte auf die psychische Belastung bei Brustkrebspatient*innen durch altersbedingte Nutzungsunterschiede der PINK! Coach App

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.